Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5DRMY)

• Drug Name: P1101 Drug Info
• Synonyms: N-Phenylethylenediamine; 1664-40-0; N1-Phenylethane-1,2-diamine; N-(2-Aminoethyl)aniline; 1,2-Ethanediamine, N-phenyl-; Ethylenediamine, N-phenyl-; N-Phenyl-1,2-ethanediamine; 1,2-Ethanediamine, N1-phenyl-; Benzenamine, N-(2-aminoethyl)-; N'-phenylethane-1,2-diamine; N-phenylethane-1,2-diamine; n1-phenyl-1,2-ethanediamine; MFCD00008162; (2-aminoethyl)phenylamine; N-Phenylethylenediamine, 99%; NSC84247; phenylethylenediamine; EINECS 216-773-4; NSC 84247; 2-phenylaminoethylamine; phenyl ethylene diamine; ACMC-209duf; N -phenylethylenediamine; N-phenyl ethylenediamine; N-phenyl ethylene diamine; N-phenyl-ethylene-diamine; N-(2-aminoethyl)-aniline; N-phenyl ethyl-ene diamine; n2-phenyl-1,2-ethanediamine; N-phenyl-ethane-1,2-diamine; SCHEMBL307775; N-Phenylethylenediamine, 98%; N'-phenyl-ethane-1,2-diamine; N1-phenyl-ethane-1,2-diamine; DTXSID1061861; OCIDXARMXNJACB-UHFFFAOYSA-; Ethylenediamine, N-phenyl- (8CI); STR05027; ZINC1736738; 8473AA; ANW-22213; NSC-84247; SBB004200; STL257388; AKOS005135725; LS10740; MCULE-5870561171; NE53436; AC-25457; AK122216; SY009366; DB-043652; CS-0045385; FT-0629102; ST45237853; EN300-81504; J-010281

Indication

Disease Entry	ICD 11	Status	REF
Polycythemia vera	2A20.4	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 74270
  CAS Number: CAS 1664-40-0
  TTD Drug ID: DM5DRMY

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon alpha (IFNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Interferon alfa-n3	DMTZNQ9	Human immunodeficiency virus infection	1C62	Approved	[3]
Alfaferone	DMCKPUR	Hairy cell leukaemia	2A82.2	Approved	[4]
Human interferon alpha oral	DMKQ3MC	Hepatitis C virus infection	1E51.1	Phase 2	[5]
IFN-alpha	DM4H8EZ	Hepatitis C virus infection	1E51.1	Phase 2	[6]
Rontalizumab	DMBJN19	Systemic lupus erythematosus	4A40.0	Phase 2	[7]
Interferon-alpha lozenge	DM8YF01	Behcet disease	4A62	Phase 2	[8]
IFN alpha kinoid	DMLEVFW	Human immunodeficiency virus infection	1C62	Phase 1/2	[9]
NG-641	DMITVHM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
AGS-009	DMU21JF	Systemic lupus erythematosus	4A40.0	Phase 1	[11]
Ad-IFN-alpha	DMM45P9	Bladder cancer	2C94	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon alpha (IFNA)	TT95SOA	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT01949805) Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV). U.S. National Institutes of Health.
• [2] Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
• [3] Clinical pipeline report, company report or official report of Hemispherx Biopharma.
• [4] Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
• [5] Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
• [6] WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
• [7] Clinical pipeline report, company report or official report of Genentech (2011).
• [8] Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
• [9] Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
• [10] Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
• [11] Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
• [12] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.